ChromaDex Co. (NASDAQ:CDXC – Get Free Report) was the target of a large decline in short interest in October. As of October 15th, there was short interest totalling 2,960,000 shares, a decline of 7.5% from the September 30th total of 3,200,000 shares. Based on an average trading volume of 264,700 shares, the short-interest ratio is currently 11.2 days. Approximately 6.2% of the company’s stock are sold short.
ChromaDex Trading Up 1.1 %
NASDAQ CDXC traded up $0.04 during trading on Wednesday, hitting $3.66. 88,676 shares of the company traded hands, compared to its average volume of 296,204. ChromaDex has a 12 month low of $1.28 and a 12 month high of $4.65. The business has a fifty day simple moving average of $3.48 and a 200 day simple moving average of $3.22. The company has a market capitalization of $276.47 million, a P/E ratio of -72.40 and a beta of 1.86.
Insider Transactions at ChromaDex
In related news, Director Kristin Patrick sold 23,000 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 9.64% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On ChromaDex
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of ChromaDex in a report on Friday, August 9th.
Check Out Our Latest Stock Report on ChromaDex
About ChromaDex
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
See Also
- Five stocks we like better than ChromaDex
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- How Can Investors Benefit From After-Hours Trading
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Differences Between Momentum Investing and Long Term Investing
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.